Cit­ing 's­trate­gic con­sid­er­a­tions,' Ab­b­Vie breaks off Parkin­son's deal with biotech part­ner

Ab­b­Vie, one of the first Big Phar­mas to bet on al­pha-synu­cle­in as a tar­get for Parkin­son’s dis­ease, seems to be cool­ing on the field.

The phar­ma gi­ant is drop­ping its col­lab­o­ra­tion with Swe­den’s BioArc­tic around a port­fo­lio of al­pha-synu­cle­in an­ti­bod­ies, in­clud­ing one that it pre­vi­ous­ly said was ready to go in­to Phase II. A clin­i­cal­tri­als.gov list­ing for AB­BV-0805 says a Phase I study is “With­drawn (Strate­gic con­sid­er­a­tions).”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER